Evidence map›Paper›PMID 27936164›Full record

ArticlePloS one2016

Transcriptome and Metabolome Analyses in Exogenous FABP4- and FABP5-Treated Adipose-Derived Stem Cells.

Tokunori Yamamoto, Masato Furuhashi, Takeshi Sugaya, Tsuyoshi Oikawa, Megumi Matsumoto, Yasuhito Funahashi, Yoshihisa Matsukawa, Momokazu Gotoh, Tetsuji Miura

Open access · goldAbstract read
In one paragraph

Article in PloS one, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 21 papers.

0numbers the graph read from it
0cells of the map it votes in
21citing papers in PubMed
2.3field-weighted citation impact, top 12% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

21 citing papers in PubMed, 36 citations in OpenAlex.

  1. Trial
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Article
  10. Article
  11. Article
  12. Article
  13. Article
  14. Review
  15. Article
  16. Article
  17. Article
  18. Fatty Acid-Binding Protein 4 in Cardiovascular and Metabolic Diseases.Journal of atherosclerosis and thrombosis · 2019
    Review
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 3 institutions in 1 country.

Tokunori YamamotoDepartment of Urology, Nagoya University Graduate School of Medicine, Nagoya, Japan.
Masato FuruhashiDepartment of Cardiovascular, Renal and Metabolic Medicine, Sapporo Medical University School of Medicine, Chuo-ku, Sapporo, Japan.
Takeshi SugayaDepartment of Nephrology and Hypertension, St. Marianna University School of Medicine, Sugao, Miyamae-ku, Kawasaki, Kanagawa, Japan.
Tsuyoshi OikawaCIMIC Co., Ltd; Mass Building Yushima, Bunkyo-ku, Tokyo, Japan.
Megumi MatsumotoDepartment of Cardiovascular, Renal and Metabolic Medicine, Sapporo Medical University School of Medicine, Chuo-ku, Sapporo, Japan.
Yasuhito FunahashiDepartment of Urology, Nagoya University Graduate School of Medicine, Nagoya, Japan.
Yoshihisa MatsukawaDepartment of Urology, Nagoya University Graduate School of Medicine, Nagoya, Japan.
Momokazu GotohDepartment of Urology, Nagoya University Graduate School of Medicine, Nagoya, Japan.
Tetsuji MiuraDepartment of Cardiovascular, Renal and Metabolic Medicine, Sapporo Medical University School of Medicine, Chuo-ku, Sapporo, Japan.
Nagoya University · JPSapporo Medical University · JPBunkyo University · JP

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Adipose-derived stem cells (ADSC), which exist near adipocytes in adipose tissue, have been used as a potential tool of regenerative medicine. Lipid chaperones, fatty acid-binding protein 4 (FABP4) and 5 (FABP5), are abundantly expressed in adipocytes. FABP4 has recently been shown to be secreted from adipocytes during lipolysis in a non-classical pathway and may act as an adipokine. Here, we investigated the role of exogenous FABP4 and FABP5 in transcriptional and metabolic regulation in ADSC. FABP4 and FABP5 were little expressed in ADSC. However, both FABP4 and FABP5 were significantly induced after adipocyte differentiation of ADSC and were secreted from the differentiated adipocytes. Analysis of microarray data, including gene ontology enrichment analysis and cascade analysis of the protein-protein interaction network using a transcription factor binding site search, demonstrated that treatment of ADSC with FABP4 or FABP5 affected several kinds of genes related to inflammatory and metabolic responses and the process of cell differentiation. Notably, myogenic factors, including myocyte enhancer factors, myogenic differentiation 1 and myogenin, were modulated by treatment of ADSC with FABP4, indicating that exogenous FABP4 treatment is partially associated with myogenesis in ADSC. Metabolome analysis showed that treatment of ADSC with FABP4 and with FABP5 similarly, but differently in extent, promoted hydrolysis and/or uptake of lipids, consequentially together with enhancement of β oxidation, inhibition of downstream of the glycolysis pathway, accumulation of amino acids, reduction of nucleic acid components and increase in the ratio of reduced and oxidized nicotinamide adenine dinucleotide phosphates (NADPH/NADP+), an indicator of reducing power, and the ratio of adenosine triphosphate and adenosine monophosphate (ATP/AMP), an indicator of the energy state, in ADSC. In conclusion, secreted FABP4 and FABP5 from adipocytes as adipokines differentially affect transcriptional and metabolic regulation in ADSC near adipocytes. The adiposity condition in the host of regenerative medicine may affect characteristics of ADSC by exposure of the balance of FABP4 and FABP5.

Indexed as

MetabolomeTranscriptomeAdipocytesCell DifferentiationCell LineFatty Acid-Binding ProteinsGene ExpressionHumansRecombinant ProteinsStem CellsFABP4 protein, humanFABP5 protein, humanFatty Acid-Binding ProteinsRecombinant Proteins

Identifiers

PMID27936164
PMCPMC5148007
OpenAlexW2560453428

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.